B04-furin-inhibited-car-macrophages
Michel Salzet, Lydia Ziane Chaouche, Marie Duhamel
WO 2025/177014 A1
https://patents.google.com/patent/WO2025177014A1/en
Abstract
Furin, a proprotein convertase, is over-expressed in human primary macrophages exposed to tumour cells and redirects them towards an anti-inflammatory, tumour-permissive phenotype. Inhibiting furin keeps CAR macrophages derived from primary blood monocytes in a pro-inflammatory state even in a tumour cell environment.
The resulting furin-inhibited CAR-M show enhanced phagocytic activity against breast cancer cell lines and patient-derived tumoroids, and their secretome enhances T-cell proliferation — a second-generation CAR-M strategy for solid tumours. Claim 1 covers the pharmaceutical composition itself.
Patent family
| Publication number | Office | Kind | Published |
|---|---|---|---|
| WO 2025/177014 A1 | WIPO | Application | 2025-08-28 |
- Priority date — 23 February 2024
- Filing date — 23 February 2024
- Status — Pending (PCT)
- Applicants — Inserm, CHU de Lille, Université de Lille
- Research axis — Immunotherapy & tumour targets
Context
The therapeutic vector on which WO 2026/058015 builds: the macrophage platform is protected here, the HLA-H / HLA-J targets there.
Abstract as published
CAR macrophages (CAR-M) can phagocyte tumor cells expressing a target antigen. It is herein shown that the proprotein convertase furin is over-expressed in human primary macrophages in the presence of tumor cells, which is a way to redirect these macrophages towards an anti-inflammatory phenotype. Conversely, inhibition of furin leads to the maintenance of their pro-inflammatory phenotype, even in a tumor cell environment. The present invention proposes to use furin-inhibited CAR-M derived from primary blood monocytes as a therapeutic strategy to treat solid tumors.